Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities

(marketscreener.com) -- New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function ---- New preliminary safety analyses demonstrated no detected off-target activity in Prime Edited Wilson’s disease cells ---- New data leveraging PASSIGE...https://www.marketscreener.com/quote/stock/PRIME-MEDICINE-INC-145651542/news/Prime-Medicine-Announces-Recent-Progress-and-Highlights-2023-Strategic-Priorities-42691438/?utm_medium=RSS&utm_content=20230109